Adicet Bio moved -6.5% this afternoon session, trading between a high of $6.71 and a low of $6.195 per share. Yesterday the stock finished at $6.67 per share, compared to an average analyst target price of $26.75.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The small-cap biotechnology: pharmaceutical preparations company is based in the United States. Adicet Bio has trailing twelve months earnings per share (EPS) of -2.66, which at today's prices amounts to a price to earnings (P/E) ratio of -2.3.
Snapshot of Adicet Bio's Operating Margins:
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 24,990 | 97,541 | -290.32 | 54.02 |
| 2021-12-31 | 9,730 | 71,163 | -631.38 | -188.42 |
| 2020-12-31 | 17,903 | 57,094 | -218.91 | 93.06 |
| 2019-12-31 | 995 | 32,383 | -3154.57 | n/a |
Averaging out to -1073.8% over the last 4 years, Adicet Bio's operating margins also have a high coefficient of variability, which stands at 130.3%. On the other hand, we note that the firm's margins are growing at a 44.9% compounded average yearly rate.
